<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875533</url>
  </required_header>
  <id_info>
    <org_study_id>B7471009</org_study_id>
    <nct_id>NCT04875533</nct_id>
  </id_info>
  <brief_title>20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan</brief_title>
  <official_title>A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 60 YEARS OF AGE AND OLDER IN JAPAN, KOREA, AND TAIWAN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a&#xD;
      20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age&#xD;
      and older in Japan, Korea, and Taiwan&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">March 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted local reactions within 10 days after vaccination (redness,swelling, and pain at the injection site)</measure>
    <time_frame>10 days after Vaccination 1</time_frame>
    <description>Prompted local reactions after Vaccination 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted systemic events within 7 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain)</measure>
    <time_frame>7 days after Vaccination 1</time_frame>
    <description>Prompted systemic events after Vaccination 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting adverse events (AEs) within 1 month after vaccination</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>AEs occurring within 1 month after Vaccination 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting serious adverse events (SAEs) within 1 months after Vaccination 1</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>SAEs occurring within 1 month after Vaccination 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serotype-specific OPA geometric mean titer (GMT) ratios 1 month after vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>OPA GMT ratios 1 month after vaccination between the 20vPnC and 13vPnC for the 13 matched serotypes and 1 month after vaccination between 20vPnC and PPSV23 for the 7 additional serotypes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific OPA GMTs 1 month after vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>OPA GMTs 1 month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in serotype-specific OPA titers from before to 1 month after vaccination</measure>
    <time_frame>From before to 1 month after vaccination</time_frame>
    <description>GMFR in OPA titers 1 month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥4-Fold rise in serotype-specific OPA titers from before to 1 month after vaccination</measure>
    <time_frame>From before to 1 month after vaccination</time_frame>
    <description>Participants with ≥4-fold rise in OPA titers 1 month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific OPA titers greater than or equal to the lower limit of quantitation (LLOQ) 1 month after vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Participants with OPA titers greater than or equal to LLOQ 1 month after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting prompted local reactions within 10 days after vaccination (redness,swelling, and pain at the injection site) in participants enrolled from Japan sites</measure>
    <time_frame>10 days after Vaccination 2</time_frame>
    <description>Prompted local reactions after Vaccination 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects reporting prompted systemic events within 7 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain) in participants enrolled from Japan sites</measure>
    <time_frame>7 days after Vaccination 2</time_frame>
    <description>Prompted systemic events after Vaccination 2.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Pneumococcal Disease</condition>
  <arm_group>
    <arm_group_label>20vPnC/Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20vPnC and saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13vPnC/PPSV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13vPnC and PPSV23</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>20vPnC</intervention_name>
    <description>20vPnC</description>
    <arm_group_label>20vPnC/Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline</description>
    <arm_group_label>20vPnC/Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13vPnC</intervention_name>
    <description>Pneumococcal conjugate vaccine</description>
    <arm_group_label>13vPnC/PPSV23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPSV23</intervention_name>
    <description>Pneumococcal polysaccharide vaccine</description>
    <arm_group_label>13vPnC/PPSV23</arm_group_label>
    <other_name>Pneumovax 23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Male or female participants 60 years of age and older at the time of consent.&#xD;
&#xD;
          -  Adults determined by clinical assessment, including medical history and clinical&#xD;
             judgment, to be eligible for the study, including adults with preexisting stable&#xD;
             disease, defined as disease not requiring significant change in therapy in the&#xD;
             previous 6 weeks or hospitalization for worsening disease within 12 weeks before&#xD;
             receipt of study intervention. (For adults 60 through 64 years of age to be enrolled&#xD;
             at Japan sites: Participants must have a preexisting chronic stable disease with an&#xD;
             elevated risk for pneumococcal disease.)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of microbiologically proven invasive disease caused by S pneumoniae.&#xD;
&#xD;
          -  Serious chronic disorder, including metastatic malignancy, severe COPD requiring&#xD;
             supplemental oxygen, end-stage renal disease with or without dialysis, cirrhosis of&#xD;
             the liver, clinically unstable cardiac disease, or any other disorder that, in the&#xD;
             investigator's opinion, excludes the participant from participating in the study.&#xD;
&#xD;
          -  Previous vaccination with any licensed or investigational pneumococcal vaccine, or&#xD;
             planned receipt through study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seishinkai Inoue Hospital</name>
      <address>
        <city>Itoshima</city>
        <state>Fukuoka</state>
        <zip>819-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Women's Clinic LUNA NEXT STAGE</name>
      <address>
        <city>Naka-ku, Yokohama-Shi</city>
        <state>Kanagawa</state>
        <zip>231-0861</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Sakura Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>P-one Clinic, Keikokai Medical Corporation</name>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <zip>1920071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sone Clinic Shinjuku</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan-si</city>
        <state>Gyeonggi-do</state>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [seoul]</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07441</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Mokdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>New Taipei City,</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7471009</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

